Active Ingredient History

NOW
  • Now
Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography.   NCATS

  • SMILES: CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCCO)=C1I
  • InChIKey: UUMLTINZBQPNGF-UHFFFAOYSA-N
  • Mol. Mass: 791.1119
  • ALogP: -0.99
  • ChEMBL Molecule:
More Chemistry
  • Mechanisms of Action: Missing data
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No
5-(n-2,3-dihydroxypropylacetamido)-2,4,6-triiodo-n-(2-hydroxyethyl)-n'-(2,3-dihydroxypropyl)isophthalamide | ioxilan | ioxilane | ioxilanum | ioxitol | n-(2,3-dihydroxypropyl)-n’-(2- hydroxyethyl)-5-[n-(2,3-dihydroxypropyl) acetamido]-2,4,6-triiodoisophthal-amide | oxilan | oxilan-300 | oxilan-350

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue